Bortezomib successfully reduces monoclonal serum free light chain levels in a patient with recurrent myeloma and cast nephropathy in the renal transplant.

Clinical transplants

Volumn , Issue , 2009, Pages 439-441

  Kumar, Vineeta ^a   Elkins, Stephanie ^b   Gaston, Robert S ^b   Prendergast, Mary B ^b   Reddy, Vishnu ^b   Cook, William J ^b   Sanders, Paul W ^b  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BORONIC ACID DERIVATIVE; BORTEZOMIB; CANCER ANTIBODY; DRUG DERIVATIVE; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; SYNDECAN 1; TACROLIMUS;

ADULT; ARTICLE; BIOPSY; BONE MARROW; CASE REPORT; CHRONIC KIDNEY FAILURE; FEMALE; HUMAN; IMMUNOLOGY; KIDNEY TRANSPLANTATION; LIVING DONOR; MULTIPLE MYELOMA; PATHOLOGY; RECURRENT DISEASE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BIOPSY; BONE MARROW; BORONIC ACIDS; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVING DONORS; MULTIPLE MYELOMA; MYCOPHENOLIC ACID; PROTEASE INHIBITORS; PYRAZINES; RECURRENCE; SYNDECAN-1; TACROLIMUS;

EID: 77954613992     PISSN: 08909016     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)